Cargando…
Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the commonest inherited disorder of the kidneys. A vasopressin V2-receptor antagonist (tolvaptan) was recently approved for the treatment of ADPKD. This study aims to analyze the safety and tolerability of tolvaptan for the manage...
Autores principales: | Guerra-Torres, Xavier E, Peña Esparragoza, J, Perez Fernandez, M, Fernandez Rodríguez, M, Mancha Ramos, J, Martinez Miguel, P, Rodriguez Puyol, D, Bouarich, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532866/ https://www.ncbi.nlm.nih.gov/pubmed/33033683 http://dx.doi.org/10.7759/cureus.10207 |
Ejemplares similares
-
Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022) -
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017) -
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021) -
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023) -
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)